Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 7/20 | 0.45 |
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | TAF1 | P21675 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.40 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.40 |
| ▸ | HIPK3 | Q9H422 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24199719 | 0.82 | HTR2C (0.42) | DRD2SIGMAR1DRD3 | |
| SCHEMBL11619057 | 0.80 | HTR2C (0.61) | QDPRDRD2DRD3 | |
| SCHEMBL6348724 | 0.79 | HDAC4 (0.52) | DRD2DRD3 | |
| SCHEMBL21363222 | 0.79 | HDAC4 (0.47) | DRD2DRD3 | |
| SCHEMBL12825091 | 0.79 | QDPR (0.53) | QDPRDRD2HTR6TAF1SIGMAR1 | |
| SCHEMBL10078397 | 0.79 | QDPR (0.53) | QDPRDRD2HTR6 | |
| SCHEMBL10274630 | 0.79 | DRD2 (0.69) | QDPRDRD2SIGMAR1DRD3 | |
| SCHEMBL1427525 | 0.79 | DRD2 (0.56) | QDPRDRD2HTR6TAF1SIGMAR1 | |
| SCHEMBL10078845 | 0.79 | QDPR (0.53) | QDPRDRD2DRD3 | |
| SCHEMBL29780589 | 0.79 | DRD2 (0.56) | QDPRDRD2HTR6TAF1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | QDPR 2565/4885DRD2 4834/4885HTR6 3206/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | QDPR 2565/4885DRD2 4834/4885HTR6 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.